儿童肺炎支原体肺炎临床路径实施效果评价及变异原因分析

Evaluation on the Implementation Effect of Clinical Pathway for Children with Mycoplasma Pneumoniae Pneumonia and Analysis on Variation Causes

目的 :评估儿童肺炎支原体肺炎(MPP)临床路径的实施效果及分析变异原因。方法 :采用回顾性研究方法,分析未采用临床路径治疗的107例(对照组)和经临床路径治疗的75例(研究组)MPP患儿在住院时间、住院费用、药品费用、检查费用等方面的差异,并探讨临床路径变异情况。结果 :两组住院费用比较,差异无统计学意义(P> 0.05);研究组住院时间、药品费用显著少于对照组,检查费用高于对照组,差异有统计学意义(P <0.05);研究组临床路径变异率为76.00%。结论 :实施儿童MPP临床路径可缩短住院时间,降低药品费用,增高检查费用,对总住院费用影响不大;该路径在临床实施过程中变异率较高,仍需进一步完善。

Objective:To evaluate the implementation effect of clinical pathway for children with Mycoplasma pneumoniae pneumonia(MPP)and analyze variation causes.Methods:A retrospective study was conducted to analyze the differences in hospitalization time,hospitalization cost,drug cost and examination cost between 107 children with MPP who were not treated by clinical pathway(control group)and 75 children who were treated by clinical pathway(study group)and to explore the variation of clinical pathway.Results:There was no statistically significant difference in hospitalization cost between the two groups(P>0.05).The hospitalization time and drug cost in the study group were significantly lower than those in the control group,while the examination cost was higher than that in the control group,with statistically significant differences(P<0.05).The clinical pathway mutation rate in the study group was 76.00%.Conclusion:The implementation of the clinical path for children with MPP can shorten hospitalization time,reduce drug cost and increase examination cost,and has little effect on total hospitalization cost.The pathway has a high variation rate during clinical implementation and it still needs further improvement.